MEDCO/PAID HAS HIGHEST USE OF LESCOL AMONG TOP RETAIL PBMs, IMS DATA SHOW; GENERIC PENETRATION OF CIMETIDINE IS SIMILAR IN CASH AND MANAGED CARE MARKETS
Executive Summary
Value Health's promotion of Sandoz' HMG-CoA reductase inhibitor Lescol following the drug's April 1994 launch did not result in increased use of Lescol on ValueRx formularies compared to other pharmacy benefit management companies, IMS market share data for 1994 show.